Rollover study offers continued itacitinib access for chronic disease patients

NCT ID NCT04640025

Terminated Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study provides continued access to itacitinib for 18 patients who were already benefiting from the drug in earlier trials. Participants have myelofibrosis, chronic graft-versus-host disease, or bronchiolitis obliterans after lung transplant. They continue their same dose as long as they tolerate it and see benefit. The main goal is to track side effects over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: itacitinib (a drug taken orally as a tablet)
What this could lead to: If successful, this study could show that long-term itacitinib is safe and helps control these chronic conditions.
What could go wrong: This is a small, early-phase rollover study that was terminated early, so results may be limited. Itacitinib may cause side effects and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bronchiolitis Obliterans bronchiolitis obliterans syndrome chronic graft versus host disease myelofibrosis primary myelofibrosis transplant-related bronchiolitis obliterans

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC GRAFT VERSUS HOST DISEASE MYELOFIBROSIS POSTLUNG TRANSPLANT (BRONCHIOLITIS OBLITERANS)

Contacts and locations

Locations

Anschutz Cancer Pavilion-University of Colorado

Aurora, Colorado, 80045, United States
Aou San Giovanni Di Dio E Ruggi

Salerno, 84131, Italy
Azienda Ospedaliera Bianchi-Melacrino-Morelli Ospedali Riuniti

Reggio Calabria, 89100, Italy
Azienda Policlinico Vittorio Emanuele

Catania, 95123, Italy
City of Hope National Medical Center

Duarte, California, 31010, United States
Cleveland Clinic

Cleveland, Ohio, 44195, United States
Hadassah Hebrew University Medical Center Ein Karem Hadassah

Jerusalem, 91120, Israel
Hospital Universitario Ramon Y Cajal

Madrid, 28034, Spain
Hospital Universitario Virgen de Las Nieves

Granada, 18012, Spain
Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Ordensklinikum Linz Gmbh Elisabethinen

Linz, 04020, Austria
Parkview Cancer Institute

Fort Wayne, Indiana, 46845, United States
Providence Health

Vancouver, British Columbia, V6Z 2A5, Canada
Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States
Temple University Department of Thoracic Medicine and Surgery

Philadelphia, Pennsylvania, 19140, United States
Texas Oncology San Antonio

San Antonio, Texas, 78240, United States
Universitaire Ziekenhuis Leuven - Gasthuisberg

Leuven, 03000, Belgium
Universitatsklinikum Halle (Saale)

Halle, D06120, Germany
University Hospital Mannheim

Mannheim, 68167, Germany
University Hospital of West Attica - Attikon

Chaïdári, 12462, Greece
University Medical Centre Hamburg-Eppendorf Centre of Oncology

Hamburg, 20251, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.